Corcept Therapeutics is trading at $112.61, down 4.17%, as broader risk-off trading pressured biotech shares.
- No credible company-specific negative announcement was identified for September 23, 2026; recent Corcept news was constructive, including an EMA recommendation for relacorilant.
- Biotechnology shares weakened alongside major indexes as the 10-year Treasury yield approached 4.99%, pressuring growth-oriented healthcare valuations.
- Elevated oil prices and renewed inflation concerns added to macro pressure.